Symptoms of PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR Test
The PML RARA t(15;17)(q22;q12) gene rearrangement is a critical biomarker for diagnosing acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML). This specific genetic anomaly involves a translocation between chromosomes 15 and 17, leading to the creation of the PML-RARA fusion gene. This genetic alteration plays a pivotal role in the development of APL by disrupting the normal function of cells in the bone marrow. The Quantitative PCR Test for this gene rearrangement is a sophisticated diagnostic tool used to detect the presence of the PML-RARA fusion gene, thereby confirming the diagnosis of APL. The test cost is set at 1220 AED, reflecting the comprehensive analysis and accurate results it provides. For more information, visit DNA Labs UAE.
Understanding the Symptoms of APL
Identifying the symptoms of acute promyelocytic leukemia is crucial for early diagnosis and treatment. APL can present a variety of symptoms, some of which are common to other types of leukemia, while others are more specific to APL. Recognizing these symptoms can prompt individuals to seek medical attention, leading to timely diagnosis and treatment.
- Fatigue and Weakness: A common symptom due to anemia, a condition characterized by a decrease in red blood cells.
- Fever and Infections: Frequent or severe infections are common due to a reduction in healthy white blood cells that fight infection.
- Bleeding and Bruising: APL patients often experience easy bruising, bleeding gums, or nosebleeds due to a decrease in platelets.
- Weight Loss: Unintended weight loss without a change in diet or exercise routine.
- Shortness of Breath: Occurs due to anemia and the body’s inability to supply enough oxygen to tissues.
- Bone or Joint Pain: Pain in bones and joints can occur as a result of leukemia cells spreading to these areas.
It’s important to note that these symptoms can also be associated with other health conditions. Therefore, the presence of these symptoms alone does not confirm APL. A definitive diagnosis can only be made through specific tests, including the PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR Test.
Importance of Early Diagnosis and Treatment
Early diagnosis and treatment of APL are vital for improving patient outcomes. The PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR Test plays a crucial role in the early detection of APL. By identifying the specific genetic mutation responsible for APL, healthcare providers can tailor treatment strategies to target the root cause of the disease. Treatment for APL often includes chemotherapy, arsenic trioxide, and all-trans retinoic acid (ATRA) therapy, which have been shown to be highly effective, especially when initiated early in the disease course.
Given the significance of timely and accurate diagnosis, the cost of 1220 AED for the PML RARA t(15;17)(q22;q12) Gene Rearrangement Quantitative PCR Test is a valuable investment in health. This test not only aids in confirming the diagnosis of APL but also in monitoring the disease’s response to treatment and detecting any potential relapse. For those experiencing symptoms or at risk of APL, seeking medical advice and considering this test could be a critical step towards achieving a positive outcome.
For further details on the test and to schedule an appointment, please visit DNA Labs UAE.
